To reduce the use of Chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer | SAKK

To reduce the use of Chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer

IBCSG 55-17 TOUCH

Coordinating investigator

Dr. med.

Patrik

Weder

Brustzentrum Ostschweiz AG

+41 71 552 33 33

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer

For further information on the IBCSG 55-17 TOUCH trial, please consult the IBCSG website.

Clinics

All trials

More trials: Breast cancer

Treatment of patients with bone metastases using Xgeva®

SAKK 96/12

A phase I trial with TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors

SAKK 65/16

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

SAKK 23/16 TAXIS

Metastatic breast cancer: chemotherapy or anti-hormonal treatment in combination with ribociclib

SAKK 21/18

Palbociclib for patients with hormone receptor positive / HER2-negative breast cancer that has recurred after surgical removal (POLAR)

IBCSG 59-19 POLAR

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

SAKK 23/18